FIG 1.
Distribution of HAR FLT3/ITD+ AML patients included in analysis. (A) CONSORT diagram of AAML1031 overall and by Arm C cohort, (B) Flow diagram of AAML1031 Arms A/B (sorafenib-unexposed), and (C) Flow diagram for AAML0531 (sorafenib-unexposed). Alt, alternative donor (donor availability defined for intermediate- and high-risk patients only); AML, acute myeloid leukemia; HAR, high allelic ratio; HSCT, hematopoietic stem-cell transplant; MFD, matched family donor.